Henry Witlock Moriarty II, 75, of Warrior Run, passed away unexpectedly Saturday, April 3, 2021, in Geisinger South Wilkes-Barre Hospital.
Henry was born Oct. 21, 1945, in Rennes, France. He later moved to Alexandria, Va., where he grew up with his five brothers and sisters, running the streets of the post-war baby boom town with scores of other neighborhood children whose antics peppered the many stories Henry loved to share with his family, friends and students.
Henry is survived by his wife of 49 and a half years, Fran (Zbieg) âBujiâ Moriarty; daughter, Katie Moriarty-de Biasi, Ph.D.; and son-in-law, Stefan, Kirchheim unter Teck, Germany; and son, Brendan Moriarty and his fiancée, Aisling Carroll, both of Philadelphia; loved-beyond-the-moon-and-back little ones (grandchildren), Henry and Tessa de Biasi; brother, Paul Moriarty (and Cynthia), Woodbridge, Va.; sisters, Mary Frances Thompson (and Vernon); Bridget Moriarty, both of Georgetown, Texas; numerous nieces, nep
DA: Bail bondsman was justified in fatal Nanticoke shooting
citizensvoice.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citizensvoice.com Daily Mail and Mail on Sunday newspapers.
Police: Man shot by bail bondsman in Nanticoke dies
citizensvoice.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citizensvoice.com Daily Mail and Mail on Sunday newspapers.
Another local medical provider is offering an intravenous antibody therapy that may help COVID-19 patients avoid hospital stays and recover more quickly with fewer complications.
The Wright Center for Community Health is now operating a Scranton outpatient infusion clinic administering the monoclonal antibody bamlanivimab, which received emergency use authorization as a COVID-19 treatment in November.
âMonoclonal antibodies are laboratory-made proteins that mimic the immune systemâs ability to fight off harmful pathogens like viruses,â according to the U.S. Food and Drug Administration. Developed by the pharmaceutical firm Eli Lilly and Co., bamlanivimab is a monoclonal antibody specifically directed against the spike protein of SARS-CoV-2, the virus that causes COVID-19. Itâs âdesigned to block the virusâ attachment and entry into human cells,â according to the FDA.